Global Visceral Pain Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Visceral Pain treatment during 2019. Clinical development activities are being undertaken by more than 20 companies including Addex Therapeutics Ltd, Algomedix Inc, Anavex Life Sciences Corp, Arena Pharmaceuticals Inc, Astellas Pharma Inc and others.
A Significant contribution to the Visceral Pain pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Visceral Pain pipeline included 21 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Visceral Pain condition and increased access to investments is encouraging growth of Visceral Pain drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Visceral Pain drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Visceral Pain therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Visceral Pain pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Visceral Pain. Further, orphan drug status, fast track designation, grants awarded and other special status for Visceral Pain pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Visceral Pain pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Visceral Pain Pipeline candidates-
A Significant contribution to the Visceral Pain pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Visceral Pain pipeline included 21 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Visceral Pain condition and increased access to investments is encouraging growth of Visceral Pain drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Visceral Pain drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Visceral Pain therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Visceral Pain pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Visceral Pain. Further, orphan drug status, fast track designation, grants awarded and other special status for Visceral Pain pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Visceral Pain pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Visceral Pain Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Visceral Pain drugs
- Late phase: Phase 3 and in-approval Visceral Pain drugs
- Company overview
- Snapshot
- Visceral Pain therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Visceral Pain- Disease Overview
2.2 Visceral Pain- Pipeline Snapshot
2.3 Visceral Pain- Pipeline Drugs by Phase
2.4 Visceral Pain- Pipeline Drugs by Company
2.5 Visceral Pain- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Addex Therapeutics Ltd Visceral Pain Drug Pipeline, H2- 2019
3.2 Algomedix Inc Visceral Pain Drug Pipeline, H2- 2019
3.3 Anavex Life Sciences Corp Visceral Pain Drug Pipeline, H2- 2019
3.4 Arena Pharmaceuticals Inc Visceral Pain Drug Pipeline, H2- 2019
3.5 Astellas Pharma Inc Visceral Pain Drug Pipeline, H2- 2019
3.6 AstraZeneca Visceral Pain Drug Pipeline, H2- 2019
3.7 Cadila Healthcare Ltd Visceral Pain Drug Pipeline, H2- 2019
3.8 Chromocell Corp Visceral Pain Drug Pipeline, H2- 2019
3.9 Eisai Co Ltd Visceral Pain Drug Pipeline, H2- 2019
3.10 Eli Lilly and Co Visceral Pain Drug Pipeline, H2- 2019
3.11 Grunenthal GmbH Visceral Pain Drug Pipeline, H2- 2019
3.12 Ironwood Pharmaceuticals Inc Visceral Pain Drug Pipeline, H2- 2019
3.13 Kangen Pharmaceuticals Co Ltd Visceral Pain Drug Pipeline, H2- 2019
3.14 Kyorin Pharmaceutical Co Ltd Visceral Pain Drug Pipeline, H2- 2019
3.15 Lipella Pharmaceuticals Inc Visceral Pain Drug Pipeline, H2- 2019
3.16 NeurAxon Pharma Inc Visceral Pain Drug Pipeline, H2- 2019
3.17 Pfizer Inc Visceral Pain Drug Pipeline, H2- 2019
3.18 Pierre Fabre Pharmaceuticals Inc Visceral Pain Drug Pipeline, H2- 2019
3.19 UCB SA Visceral Pain Drug Pipeline, H2- 2019
3.20 Urigen Pharmaceuticals Inc Visceral Pain Drug Pipeline, H2- 2019
3.21 Xigen SA Visceral Pain Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Visceral Pain- Phase 1 Drug Details
4.2 Visceral Pain- Phase 1 Drug Overview
4.3 Visceral Pain- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Visceral Pain- Phase 2 Drug Details
5.2 Visceral Pain- Phase 2 Drug Overview
5.3 Visceral Pain- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Visceral Pain- Phase 3 Drug Details
6.2 Visceral Pain- Phase 3 Drug Overview
6.3 Visceral Pain- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Visceral Pain- Pre-clinical Phase Drug Details
7.2 Visceral Pain- Pre-clinical Phase Drug Overview
7.3 Visceral Pain- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Visceral Pain- Disease Overview
2.2 Visceral Pain- Pipeline Snapshot
2.3 Visceral Pain- Pipeline Drugs by Phase
2.4 Visceral Pain- Pipeline Drugs by Company
2.5 Visceral Pain- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Addex Therapeutics Ltd Visceral Pain Drug Pipeline, H2- 2019
3.2 Algomedix Inc Visceral Pain Drug Pipeline, H2- 2019
3.3 Anavex Life Sciences Corp Visceral Pain Drug Pipeline, H2- 2019
3.4 Arena Pharmaceuticals Inc Visceral Pain Drug Pipeline, H2- 2019
3.5 Astellas Pharma Inc Visceral Pain Drug Pipeline, H2- 2019
3.6 AstraZeneca Visceral Pain Drug Pipeline, H2- 2019
3.7 Cadila Healthcare Ltd Visceral Pain Drug Pipeline, H2- 2019
3.8 Chromocell Corp Visceral Pain Drug Pipeline, H2- 2019
3.9 Eisai Co Ltd Visceral Pain Drug Pipeline, H2- 2019
3.10 Eli Lilly and Co Visceral Pain Drug Pipeline, H2- 2019
3.11 Grunenthal GmbH Visceral Pain Drug Pipeline, H2- 2019
3.12 Ironwood Pharmaceuticals Inc Visceral Pain Drug Pipeline, H2- 2019
3.13 Kangen Pharmaceuticals Co Ltd Visceral Pain Drug Pipeline, H2- 2019
3.14 Kyorin Pharmaceutical Co Ltd Visceral Pain Drug Pipeline, H2- 2019
3.15 Lipella Pharmaceuticals Inc Visceral Pain Drug Pipeline, H2- 2019
3.16 NeurAxon Pharma Inc Visceral Pain Drug Pipeline, H2- 2019
3.17 Pfizer Inc Visceral Pain Drug Pipeline, H2- 2019
3.18 Pierre Fabre Pharmaceuticals Inc Visceral Pain Drug Pipeline, H2- 2019
3.19 UCB SA Visceral Pain Drug Pipeline, H2- 2019
3.20 Urigen Pharmaceuticals Inc Visceral Pain Drug Pipeline, H2- 2019
3.21 Xigen SA Visceral Pain Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Visceral Pain- Phase 1 Drug Details
4.2 Visceral Pain- Phase 1 Drug Overview
4.3 Visceral Pain- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Visceral Pain- Phase 2 Drug Details
5.2 Visceral Pain- Phase 2 Drug Overview
5.3 Visceral Pain- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Visceral Pain- Phase 3 Drug Details
6.2 Visceral Pain- Phase 3 Drug Overview
6.3 Visceral Pain- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Visceral Pain- Pre-clinical Phase Drug Details
7.2 Visceral Pain- Pre-clinical Phase Drug Overview
7.3 Visceral Pain- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
